The more protective effect in ER+ tumours is thought to result from statins lowering levels of cholesterol metabolite 27-hydroxycholesterol (27HC), a selective estrogen receptor modulator that can regulate ER-dependent tumour growth [74–76]. Here, ESR1 is linked to neoplasm.